<< Back To Search

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT04756726
Age 18 +
Sex Both
Phase Phase 1, Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on a combination of therapies that aim to improve patient outcomes and potentially lead to better management of the disease. Here are some key points about the study:
  • The study investigates a unique combination of therapies that have not been widely used together before, which may enhance their effectiveness.
  • It includes various treatment options, such as targeted therapies and immunotherapies, which work by harnessing the body's immune system to fight the disease.
  • Patients will be closely monitored throughout the study to assess the effectiveness of the treatment and any side effects that may occur.
  • The study aims to provide insights into how these therapies can be combined to improve patient responses and overall survival rates.
  • By participating in this study, patients may gain access to cutting-edge treatments that are not yet available outside of a clinical trial setting.
This study represents an important step in advancing treatment options and understanding how to better manage this condition.
Third Opinion AI Generated Synopsis

Trial Summary
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single agent and, in MM only, in combination with oral dexamethasone.
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: